ImmunityBio Reports Q2 Earnings with 60% Revenue Increase, $43M in Sales, and 246% Unit Growth

ImmunityBio reported a 60% increase in Q2 2025 revenue to $26.4 million, with year-to-date sales reaching $43 million and a 246% growth in unit volume since J-code approval. The company ended Q2 2025 with $153.7 million in cash and is expanding clinical trials globally.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, announced its financial results for the second quarter and six months ended June 30, 2025. The company reported $26.4 million in revenue for Q2 2025, representing a 60% increase from $16.5 million in the first quarter of 2025. Year-to-date sales reached approximately $43 million, while unit volume grew by 246% since the J-code approval [1].

ImmunityBio ended Q2 2025 with $153.7 million in cash, cash equivalents, and marketable securities. Additionally, the company closed an $80 million equity financing round in July 2025, with warrants that could result in an additional $96.0 million in gross proceeds [1].

The company's financial performance was driven by strong sales of ANKTIVA, its recombinant BCG therapeutic, in combination with BCG for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors. ImmunityBio also reported progress in its clinical trials, including the launch of ResQ201A, a randomized controlled trial (RCT) evaluating its IL-15 superagonist N-803 in combination with tislelizumab for second-line lung cancer in the U.S. [1].

ImmunityBio's R&D expenses increased to $55.2 million during Q2 2025, primarily due to higher manufacturing and distribution costs, as well as higher license fees. SG&A expenses decreased to $42.3 million, reflecting lower costs related to litigation settlements and commercial consulting activities [1].

The company reported a net loss of $92.6 million during Q2 2025, compared to $134.6 million during the same period in 2024. The reduction in loss was primarily driven by increased product revenue and lower SG&A expenses [1].

ImmunityBio continues to expand its clinical trials globally, with plans to submit clinical trial applications for ResQ201A in the EU and the UK, and to submit in Asia. The company is also conducting a randomized National Cancer Institute (NCI) cancer prevention clinical trial using ANKTIVA in combination with an adenovirus vaccine in 186 patients with Lynch Syndrome [1].

References:
[1] https://finance.yahoo.com/news/immunitybio-reports-q2-earnings-release-110000675.html